NASDAQ
2.80USD
-0.09 (-3.11%)
We have scored 5 news catalysts on Lexeo Therapeutics, Inc. Common Stock (LXEO) over the past 12 months. The biggest single-day move next to one of them came Jan 12, 2026, when LXEO closed −23.0%: “Gold Rises Sharply; Lyra Therapeutics Shares Plunge”. Coverage across the window leans positive (average ticker sentiment +0.22). Most of the impact sits in short squeeze potential and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
229.8M
P/E
—
EPS
—
Beta
1.64
52W range
2.55-10.99
Day range
2.73–2.90
Open
2.87
Prev close
2.89
Volume
619.4K
Avg volume
1.2M
Dividend
0.00
IPO
2023-11-03
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Lexeo Therapeutics, Inc. Common Stock — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for LXEO: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
